semaglutide – media

Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide

Encouraged by evidence of the impact that its diabetes drug semaglutide can have on obesity, with patients shedding an average of 16% of their weight in a mid-stage study, top researchers at Novo Nordisk today unveiled an ambitious late-stage strategy to make their mark in a tough, but potentially blockbuster market.
- Source: endpts
- 563
- November 22, 2017
Company Insight Novo Nordisk semaglutide
Drug can dramatically reduce weight of people with obesity

A drug that targets the appetite control system in the brain could bring about significant weight loss in people with clinical obesity, according to new research.
- Source: Sciencedaily
- 658
- October 27, 2017
obesity semaglutide weight loss
Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee

Novo Nordisk announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0 in favour of the approval of once-weekly semaglutide to improve glycaemic control in adults with type 2 diabetes. One member of the committee abstained.
- Source: finance.yahoo
- 609
- October 20, 2017
diabetes FDA New Approvals semaglutide
Blood sugar pill shows promise

The pill form of the drug semaglutide is worth pursuing as a way to control blood sugar in patients with type 2 diabetes, say researchers.
- Source: medicalnewstoday
- 587
- October 18, 2017
diabetes glycemic Phase Researches semaglutide

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.